SHENZHEN, China, Sept. 21, 2024 /PRNewswire/ -- In today's fast-paced world, maintaining health and vitality has become increasingly important, especially…
HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC -HANSIZHUANG (serplulimab) is expected to become the…